<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829136</url>
  </required_header>
  <id_info>
    <org_study_id>RG1121363</org_study_id>
    <secondary_id>NCI-2021-00842</secondary_id>
    <secondary_id>10599</secondary_id>
    <nct_id>NCT04829136</nct_id>
  </id_info>
  <brief_title>Early Enteral Nutrition for Patients Undergoing Donor Stem Cell Transplantation for Hematological Malignancies</brief_title>
  <official_title>Feasibility of Implementing Early Enteral Nutrition for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial examines early enteral nutrition for patients undergoing donor stem cell&#xD;
      transplantation for hematological malignancies. Patients undergoing donor stem cell&#xD;
      transplantation often develop oral and gastrointestinal damage from chemotherapy,&#xD;
      radiotherapy, or graft-versus-host disease that makes oral intake inadequate for meeting&#xD;
      nutritional needs, especially during the catabolic period of recovery. Parenteral&#xD;
      (intravenous) nutrition often requires a large fluid load, has been associated with increased&#xD;
      risk of infection, can be associated with metabolic complications such as hyperglycemia and&#xD;
      hypertriglyceridemia, is linked to elevated liver function tests, and may deprive the&#xD;
      gastrointestinal mucosa of factors thought to promote mucosal integrity and healing. Enteral&#xD;
      nutrition via a nasoenteric feeding tube is an alternate method of nutrition support. Giving&#xD;
      early enteral nutrition may be more tolerable for patients undergoing a stem cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive enteral nutrition via nasoenteric feeding tube starting on day 1&#xD;
      until hospital discharge.&#xD;
&#xD;
      ARM II: Patients receive standard of care nutritional support.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study participation rates</measure>
    <time_frame>60 days following transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Compliance with randomization (Number of participants)</measure>
    <time_frame>60 days following transplant</time_frame>
    <description>Medical records will be reviewed to assess compliance with the randomization, defined as receiving the assigned nutritional mode during the initial hospitalization irrespective of whether the other feeding mechanism was also used. Participants receiving both forms of nutrition will be noted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerance of early enteral nutrition (EN)</measure>
    <time_frame>60 days following transplant</time_frame>
    <description>Tolerance of early EN will be calculated as delivery of the intended amount on each day that nutritional supplementation was indicated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of comfort/distress attributed to EN</measure>
    <time_frame>60 days following transplant</time_frame>
    <description>The post-discharge questions measuring level of comfort or distress experienced with each nutritional treatment will be tabulated. The level of comfort/distress will be assessed using one scale with comfort and distress on opposite ends of a 9 point scale, 1 being comfortable and 9 being distressful.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>60 days following transplant</time_frame>
    <description>Will assess safety: including diarrhea, aspiration events, pneumonia, or tube misplacement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days receiving at least 650 mL EN</measure>
    <time_frame>60 days following transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (enteral nutrition)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive enteral nutrition via nasoenteric feeding tube starting on day 1 until hospital discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard of care nutritional support.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutritional Supplement Drink</intervention_name>
    <description>Given enteral nutrition via nasoenteric feeding</description>
    <arm_group_label>Arm I (enteral nutrition)</arm_group_label>
    <other_name>Boost</other_name>
    <other_name>Ensure</other_name>
    <other_name>polymeric enteral nutrition formula</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Standard of Care Nutritional Support</intervention_name>
    <description>Given standard of care, which may be parenteral nutrition</description>
    <arm_group_label>Arm II (standard of care)</arm_group_label>
    <other_name>hyperalimentation</other_name>
    <other_name>parenteral nutrition</other_name>
    <other_name>Total Parenteral Nutrition</other_name>
    <other_name>TPN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (enteral nutrition)</arm_group_label>
    <arm_group_label>Arm II (standard of care)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide written informed consent prior to initiation of any study procedures&#xD;
&#xD;
          -  Planned myeloablative allogeneic stem cell transplantation (note, melphalan dose of&#xD;
             140 mg/m^2 is included) with planned hospital admission for transplant&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major psychiatric diagnosis that impairs cognitive functioning or is not controlled at&#xD;
             the time of the approach, as judged by the patient's medical team&#xD;
&#xD;
          -  Currently receiving EN or parenteral nutrition (PN)&#xD;
&#xD;
          -  Physical restrictions to the placement of a nasoenteric feeding tube&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Fredricks</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Fredricks</last_name>
    <phone>206-667-1935</phone>
    <email>dfredric@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David Fredricks</last_name>
      <phone>206-667-1935</phone>
      <email>dfredric@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>David Fredricks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

